Indications
Indications and uses Human Tetanus Immunoglobulin is indicated for –
Prophylaxis of tetanus following injury in patients whose immunization is incomplete or uncertain.
Therapeutically in the treatment of tetanus.
Tetanus immunoglobulin should always be administered in conjunction with an active tetanus vaccination unless there are contraindications or confirmations of adequate vaccination.
Therapeutic Class
Vaccines, Anti-sera & Immunoglobulin
Description
Human Tetanus Immunoglobulin is a sterile solution containing human tetanus immunoglobulin which is prepared by Cohn fractionation of plasma of individuals with high titers of antibody to the tetanus antigen and heat inactivation step in manufacturing process (60°C, 10 hrs) is used to inactivate infectious agents such as Hepatitis B virus, Hepatitis C virus, Human immunodeficiency virus and so on.
Pharmacology
Human clostridium tetani toxoid immune globulin prevents tetanus toxoid from damaging tissue and producing the symptoms associated with tetanus. The immune globulin binds to tetanus toxiod, interfering with the normal interaction of the toxoid with human tissue. This prevents the toxoid from invading the nervous system and producing painful muscle spasms as well as autonomic dysfunction. The Clostridium tetani bacterium is killed either via antibiotic treatment of the host’s immune system and immune globulin-bound toxoid is likely broken down by phagocytic immune cells.
Dosage
Post-exposure prophylaxis of tetanus:
For adults and children single dose of 250 IU should be given. The dose may be increased to 500 IU in case of:
Infected wounds where surgically appropriate treatment cannot be achieved within 24 hours
Deep or contaminated wounds with tissue damage and reduced oxygen supply, as well as foreign body injury (e.g., bites, stings or shots)
Burns, congelations
Tissue necrosis
Septicaemic abortion
Adults weighing more than the average

Side Effects

Adverse reaction following administration of human tetanus immunoglobulin is infrequent and mild, but severe local and systemic reactions have occurred rarely.

Local reactions at the injection site: Local pain, tenderness or swelling.

In rare cases the following adverse reactions may occur:

Immune system disorders: Allergic reactions including fall in blood pressure, dyspnoea, cutaneous reactions, in isolated cases reaching as far as anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration of immunoglobulins.
Generalized reactions: Chills, fever, headache, malaise, nausea, vomiting, arthralgia and moderate back pain.
Heart and vascular disorders: Cardiovascular reactions particularly if the product is inadvertently injected intravascularly.

Pregnancy & Lactation

The safety for use of human tetanus immunoglobulin in human pregnancy has not been established in controlled clinical trials. Long lasting clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the fetus and the neonate are to be expected.

Sold out